[{"id":"08da958b-deab-46fd-9448-9e7d0dc1d817","acronym":"KEYNOTE B84","url":"https://clinicaltrials.gov/study/NCT04815720","created_at":"2021-03-25T11:52:15.829Z","updated_at":"2025-02-25T16:11:18.429Z","phase":"Phase 1/2","brief_title":"Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","source_id_and_acronym":"NCT04815720 - KEYNOTE B84","lead_sponsor":"Vaccinex Inc.","biomarkers":" PD-L1 • IFNG • IL6 • TNFA • CD4 • IL2 • IL10 • TGFB1","pipe":"","alterations":" ","tags":["PD-L1 • IFNG • IL6 • TNFA • CD4 • IL2 • IL10 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pepinemab (VX15)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 07/24/2024","primary_completion_date":" 07/24/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2025-01-08"},{"id":"7400d1d1-c93a-4e3e-a35d-94aa2105cdee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05378464","created_at":"2022-05-18T13:00:43.972Z","updated_at":"2024-07-02T16:34:38.084Z","phase":"Phase 1","brief_title":"Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine \u0026 Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT05378464","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2 • PGR • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive","tags":["HER-2 • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Trazimera (trastuzumab-qyyp) • pepinemab (VX15)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-06-05"},{"id":"7b34abd6-8da9-4a4f-9191-c0f7303b2139","acronym":"","url":"https://clinicaltrials.gov/study/NCT03373188","created_at":"2021-01-18T16:38:52.788Z","updated_at":"2024-07-02T16:35:13.632Z","phase":"Phase 1","brief_title":"VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer","source_id_and_acronym":"NCT03373188","lead_sponsor":"Emory University","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • pepinemab (VX15)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 12/15/2017","start_date":" 12/15/2017","primary_txt":" Primary completion: 10/28/2021","primary_completion_date":" 10/28/2021","study_txt":" Completion: 10/28/2021","study_completion_date":" 10/28/2021","last_update_posted":"2024-03-20"},{"id":"ca4fe1bd-ba88-4958-aaef-650e0cfbc7c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03769155","created_at":"2021-01-18T18:38:56.652Z","updated_at":"2025-02-25T14:27:52.949Z","phase":"Phase 1","brief_title":"VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma","source_id_and_acronym":"NCT03769155","lead_sponsor":"Emory University","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • pepinemab (VX15)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2032","study_completion_date":" 12/15/2032","last_update_posted":"2024-02-26"},{"id":"2ec7b800-d439-4f02-9434-501fd48a1955","acronym":"","url":"https://clinicaltrials.gov/study/NCT03320330","created_at":"2023-10-09T08:13:27.513Z","updated_at":"2024-07-02T16:35:34.579Z","phase":"Phase 1/2","brief_title":"Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors","source_id_and_acronym":"NCT03320330","lead_sponsor":"Children's Oncology Group","biomarkers":" SEMA4D","pipe":"","alterations":" ","tags":["SEMA4D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pepinemab (VX15)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 01/31/2018","start_date":" 01/31/2018","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-10-05"},{"id":"93cd4056-cbe5-452e-bdc9-f1bda3f5e8fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03268057","created_at":"2021-01-17T17:42:36.938Z","updated_at":"2025-02-25T16:06:50.261Z","phase":"Phase 1b","brief_title":"VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03268057","lead_sponsor":"Vaccinex Inc.","biomarkers":" KRAS • ALK • ROS1 • SEMA4D","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • ALK rearrangement","tags":["KRAS • ALK • ROS1 • SEMA4D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • pepinemab (VX15)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 10/05/2017","start_date":" 10/05/2017","primary_txt":" Primary completion: 09/09/2020","primary_completion_date":" 09/09/2020","study_txt":" Completion: 09/10/2020","study_completion_date":" 09/10/2020","last_update_posted":"2022-05-02"}]